# Study of Safety & PK of Luspatercept (ACE-536) in Pediatric Participants With Beta (β)-Thalassemia

> **NCT04143724** · PHASE2 · RECRUITING · sponsor: **Celgene** · enrollment: 99 (estimated)

## Conditions studied

- Beta-Thalassemia

## Interventions

- **DRUG:** ACE-536

## Key facts

- **NCT ID:** NCT04143724
- **Lead sponsor:** Celgene
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2019-11-07
- **Primary completion:** 2027-07-02
- **Final completion:** 2035-06-11
- **Target enrollment:** 99 (ESTIMATED)
- **Last updated:** 2026-01-06

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04143724

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04143724, "Study of Safety & PK of Luspatercept (ACE-536) in Pediatric Participants With Beta (β)-Thalassemia". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT04143724. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*